1 Selective serotonin reuptake inhibitors (SSRI) â sales, withdrawal ...
1 Selective serotonin reuptake inhibitors (SSRI) â sales, withdrawal ...
1 Selective serotonin reuptake inhibitors (SSRI) â sales, withdrawal ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
21876/Seroxat%2C+filmovertrukne+tabletter+20+mg+og+30+mg.doc<br />
2005 European medicines Agency<br />
Doc. Ref. EMEA/CHMP/PHVWP<br />
/397128/2005<br />
dependence.]<br />
Generally these<br />
events[<strong>withdrawal</strong> symptoms]<br />
are mild to moderate and are<br />
self-limiting, however in some<br />
patients they may be severe<br />
and/or prolonged.<br />
Core SPC<br />
Wording for<br />
<strong>SSRI</strong>s<br />
The first warnings about dependence with benzodiazepines came approximately 20 years after the<br />
first report showing <strong>withdrawal</strong> symptoms. This warning was based on the belief by the authorities<br />
that very few people were dependent. In contrast to this, it only took 5 years before it was<br />
communicated that <strong>withdrawal</strong> reactions were connected to <strong>SSRI</strong>s. In the meantime, however, the<br />
definition of dependence had been changed with the consequence that symptoms that formed the<br />
benzodiazepine dependence also formed the <strong>SSRI</strong> <strong>withdrawal</strong> reactions. For a longer period it was<br />
the perception of the authorities, that <strong>SSRI</strong>s <strong>withdrawal</strong> reactions only affected few patients and that<br />
the symptoms were relatively mild.<br />
There is interesting literature pertaining to the regulation of the newer antidepressants (60). It is<br />
described that the regulatory inertia was illustrated through the 2004 CSM Expert Working Group<br />
on the safety of <strong>SSRI</strong>s (61). The report pointed to lack of evidence of risk, because a number of<br />
essential studies had never been performed. Still, 10-15 years after licensing the <strong>SSRI</strong>s, the MHRA<br />
had received no convincing evidence of the incidence of <strong>SSRI</strong> <strong>withdrawal</strong> reactions.<br />
Patients reported symptoms as dependence to the <strong>SSRI</strong>s, but as the dependence definition was<br />
changed in 1987, as shown in study 2 in this thesis, the reported symptoms were not recognised as<br />
dependence but as <strong>withdrawal</strong> syndrome. However, in the WHO Uppsala Monitoring Centre<br />
database three <strong>SSRI</strong>s were among the 30 highest-ranking drugs in the list of drugs for which<br />
dependence has ever been reported by June 2002 (62).<br />
We related the findings in the documents to the risk management principle, described in legislation,<br />
and the precautionary principle, described in literature.<br />
In the light of the precautionary principle and the risk management principle, the results of our<br />
study can be understood in two ways. Seen from a precautionary principle, the drug agencies have<br />
41